Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boehringer Ingelheim
The study is Post-Marketing Surveillance on the Long-Term Use of Spiriva Respimat in Japanese patients with mild to moderate persistent asthma. The patient population who receive Spiriva Respimat and the safety profile is not expected to change. This study can investigate the safety and effectiveness of Spiriva Respimat in patients with mild to moderate persistent asthma under real-world use
Age
15–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients diagnosed with mild to moderate persistent bronchial asthma
Patient aged ≥ 15 years
Patients who are naive to Spiriva Respimat and receive Spiriva Respimat for the first time for treatment of bronchial asthma on top of at least ICS treatment.
You may not be if
Patients who have a contraindication to Spiriva Respimat defined in the package insert for Spiriva Respimat
Patients who have been enrolled in this study before.
Clareo Health | Specific Use-Result of Spiriva Respimat® in Asthmatics
